Agios Pharmaceutical (AGIO) 50.35 $AGIO Agios Reports

New Post Public Reply Private Reply Replies (0) Message Board

Jun 11, 2016 at 1:04 PM

Agios Pharmaceutical (AGIO) 50.35 $AGIO

Agios Reports Initial Data from Phase 1 Study of AG-519 in Healthy Volunteers
GlobeNewswire - Thu Jun 09, 8:21AM CDT
- Data Demonstrate Favorable Safety Profile with up to 14 Days of Daily Dosing -
AGIO: 50.35 (-5.87)

What Investors Think of These Biotech Stocks? - Genocea Biosciences, BioDelivery Sciences Intl., INSYS Therapeutics, and Agios Pharma
PR Newswire - Thu Jun 02, 7:20AM CDT
Restructuring activities within the Biotech industry as well as the nearing U.S. presidential election continues to affect the overall condition of firms in this space. But despite the uncertainties, investors see potential growth in select companies that. Today, ActiveWallSt.com reviews the performances of the following equities: Genocea Biosciences Inc. (NASDAQ: GNCA), BioDelivery Sciences International Inc. (NASDAQ: BDSI), INSYS Therapeutics Inc. (NASDAQ: INSY), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Click below to get your complimentary trade alerts:
BDSI: 2.67 (-0.18), INSY: 13.99 (-2.04), AGIO: 50.35 (-5.87), GNCA: 3.94 (-0.28)

Agios to Host Conference Call from the 21st Congress of the European Hematology Association
GlobeNewswire - Wed Jun 01, 6:01AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Saturday, June 11, 2016 at 9:30 a.m. ET to discuss clinical and preclinical data presented at the 21st Congress of the European Hematology Association (EHA) taking place June 9-12, 2016 in Copenhagen.
AGIO: 50.35 (-5.87)

Agios to Present Clinical and Preclinical Data from PKR Activators AG-348 and AG-519 at the 21st Congress of the European Hematology Association
GlobeNewswire - Thu May 19, 6:01AM CDT
Initial Data to be Presented from AG-348 Phase 2 DRIVE PK Study in PK Deficiency and AG-519 Phase 1 Healthy Volunteer Study
AGIO: 50.35 (-5.87)

Agios Strikes Metabolic Immuno-Oncology Deal with Celgene
Zacks Equity Research - Zacks Investment Research - Wed May 18, 10:00AM CDT
Agios Pharmaceuticals (AGIO) inked a metabolic immuno-oncology agreement with Celgene; Agios gained global rights to AG-120 and updated 2016 view.
ANIP: 52.05 (-1.64), RTRX: 17.40 (-0.30), AGIO: 50.35 (-5.87), CELG: 102.91 (-3.22)

Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights from 2010 Agreement
GlobeNewswire - Tue May 17, 3:01PM CDT
- New Collaboration Builds on Agios Research Platform and Leverages Celgene Capabilities; Agios to Receive $200 Million Upfront Payment -
AGIO: 50.35 (-5.87), CELG: 102.91 (-3.22), CELGZ: 1.46 (-0.04)

Agios (AGIO) Q1 Loss Lower than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Fri May 06, 9:51AM CDT
Agios Pharmaceuticals (AGIO) reported a first-quarter 2016 loss of 61 cents per share, much narrower than the Zacks Consensus Estimate of a loss of 69 cents.
ANIP: 52.05 (-1.64), RTRX: 17.40 (-0.30), AGIO: 50.35 (-5.87), CELG: 102.91 (-3.22)

Agios Pharmaceuticals reports 1Q loss
Automated Insights - Thu May 05, 2:45PM CDT
CAMBRIDGE, Mass. (AP) _ Agios Pharmaceuticals Inc. (AGIO) on Thursday reported a loss of $23.2 million in its first quarter.
AGIO: 50.35 (-5.87)

Agios Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 6:01AM CDT
Five Abstracts Accepted for Presentation at EHA in June, Including First Data from AG -348 Phase 2 DRIVE PK Study in PK Deficiency and AG-519 Phase 1 Healthy Volunteer Study
AGIO: 50.35 (-5.87)

Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 38.40 (-0.47), BIIB: 246.13 (-4.33), CNAT: 2.02 (-0.11), AMGN: 154.78 (-2.00), RPRX: 1.70 (-0.08), JNJ: 117.01 (+0.01), GILD: 84.45 (-1.32), GWPH: 89.69 (+0.24), GERN: 2.77 (-0.04), AVEO: 1.03 (-0.03), ICPT: 150.66 (-3.56), AGIO: 50.35 (-5.87), NVS: 78.94 (-1.57)

What's in Store for Agios (AGIO) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:38PM CDT
Agios Pharmaceuticals (AGIO), which is set to report first-quarter 2016 results on May 5, delivered a negative surprise of 300% last quarter.
IPXL: 32.45 (-1.11), JAZZ: 150.76 (-5.26), AGIO: 50.35 (-5.87), CELG: 102.91 (-3.22)

Agios to Webcast Conference Call of First Quarter 2016 Financial Results on May 5, 2016
GlobeNewswire - Mon May 02, 7:30AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Thursday, May 5, 2016 at 8:30 a.m. ET to report its first quarter 2016 financial results and discuss recent clinical development and corporate activities.
AGIO: 50.35 (-5.87)

Mylan (MYL) Q1 Earnings: What's in the Cards for the Stock?
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 6:20AM CDT
Mylan (MYL), which is set to report first-quarter 2016 results on May 3, delivered a negative earnings surprise of 2.40% in the last quarter.
MYL: 44.53 (-1.23), AGIO: 50.35 (-5.87), GNCA: 3.94 (-0.28), SNY: 39.41 (-1.45)

Merrimack (MACK) Q1 Earnings: What's Ahead for the Stock?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 6:06PM CDT
Merrimack (MACK) will report first-quarter 2016 earnings on May 2 after the market closes.
ZTS: 47.39 (-0.75), MACK: 6.32 (-0.24), AGIO: 50.35 (-5.87), LLY: 73.95 (-0.48)

Prothena (PRTA): What's Ahead for the Stock in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 5:42PM CDT
Prothena (PRTA) is expected to report first-quarter 2016 earnings on May 3.
ZTS: 47.39 (-0.75), AGIO: 50.35 (-5.87), PRTA: 46.52 (-0.89)

Agios Announces Initiation of Phase 1/2 Frontline Combination Study of AG-221 or AG-120 with VIDAZA(R) (azacitidine for injection) in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Not Eligible for Intensive Chemotherapy
GlobeNewswire - Wed Mar 30, 6:01AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the initiation of a Phase 1/2, multicenter, international, open-label study, sponsored by Celgene Corporation, of AG-221 or AG-120 in combination with VIDAZA (azacitidine for injection) in patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase (IDH) mutation who are not eligible for intensive chemotherapy. AG-221 and AG-120 are first-in-class, oral, selective, potent inhibitors of mutant IDH2 and IDH1, respectively, and are being developed in collaboration with Celgene.
AGIO: 50.35 (-5.87)

Agios' (AGIO) Q4 Loss Wider than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Fri Feb 19, 9:40AM CST
Agios Pharmaceuticals, Inc. (AGIO) reported a fourth-quarter 2015 loss of $1.08 per share.
GILD: 84.45 (-1.32), AGIO: 50.35 (-5.87), ANIK: 49.16 (+0.24), CELG: 102.91 (-3.22)

The Silly Reason Why Agios Pharmaceuticals Inc. Was Clobbered in January
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 06, 6:32AM CST
What: Shares of Agios Pharmaceuticals , a clinical-stage drug developer primarily focused on researching cancer and rare-disease treatments, were hammered in January, falling 35% based on data from S&P Capital IQ . The primary culprit behind...
AGIO: 50.35 (-5.87), CELG: 102.91 (-3.22)

Technical Recap on Biotechnology Equities -- Biogen, Medivation, Grifols, and Agios Pharma
ACCESSWIRE - Fri Feb 05, 7:02AM CST
NEW YORK, NY / ACCESSWIRE / February 05, 2016 / Park Lane Advisor has initiated coverage on the following equities: Biogen Inc. (NASDAQ: BIIB), Medivation Inc. (NASDAQ: MDVN), Grifols S.A. (NASDAQ: GRFS), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Free note on Biogen can be accessed at http://www.parklaneadvisor.com/ On Thursday, February 04, 2016, the NASDAQ Composite ended at 4,509.56, up 0.12%, the Dow Jones Industrial Average advanced 0.49%, to finish the day at 16,416.58, and the S&P 500 closed at 1,915.45, up 0.15%. The gains were broad based as five out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
MDVN: 60.01 (-0.09), BIIB: 246.13 (-4.33), AGIO: 50.35 (-5.87), GRFS: 16.96 (-0.23)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hugel's Sales Climb Despite Changes in Sales Models

Hugel's Financial Fortunes in a Shifting Landscape Who would've thought? That’s the vibe hugging the numbers Hugel Inc. just dropped. Their performance for the first three quarters of 2026 is in the books, and results show consolidated net sales climbing 15% year-on-year. Just how did they pull this rabbit out of the hat? Let's dissect this a bit. Cracking the Code of...

Are BWIN, LFCR, PCRX Shareholder Deals Fair?

What's Really Going On with BWIN, LFCR, and PCRX? Everyone talks about when there's smoke, there's fire. But in this case, it’s hard not to wonder if we're standing knee-deep in burning embers, or just a dusty old campfire. Halper Sadeh LLC is ringing the alarm bells for Baldwin Group, Lifecore Biomedical, and Pacira BioSciences, the trio tagged under NASDAQ: BWIN,...

MRP Securities Fraud: Investors Eye Millrose Case

Millrose's Troubles: A Closer Look at the Fraud Accusation Now, here's a pickle. Millrose Properties, Inc. (NYSE: MRP) has landed itself in hot water. We've got a bona fide class action lawsuit on our hands, and Schall, Brown & Schwartz LLP is waving the flag, rallying investors to step up and face the music. Turns out the company's talk might not have walked the walk...

Peabody's Q3 2026: Margins Climb Despite Net Loss

Tough Quarters but Promising Margins Alright, Peabody's Q3 2026 isn't the most sunshine-filled report I've laid eyes on, but it's not all shadows either. Sure, they posted a net loss of $32.8 million, better than last year's $70.1 million drain. Admit it or not, that's improvement. And yet, the real gem here is those expanding margins gleaming despite the loss-heavy...

Omnissa Expands AI Sovereignty: New Markets, New Control

Omnissa Rolls Out AI Sovereignty Across New Markets In the world of AI, where data is king and control is the crown, Omnissa is making bold moves with its latest expansion announcement. The company's Sovereign Solution (OSS) is now reaching into six fresh markets across Europe and Asia, offering organizations a vital grip on their digital domains like never before. Talk...

UN Forum Unleashes LatAm CEO Coalition for Action

Latin America Takes Center Stage When the UN turns its spotlight on a region, you know there's something afoot. Right in Montevideo, Uruguay, the United Nations Global Compact gathered a hefty crowd of over 300 leaders from diverse backgrounds—think business, finance, government, and academia. What they were brewing wasn’t just talk; it was about driving real change...

Lincoln Index Highlights Growth, But Risks Linger

Private Market Dynamics: A Mixed Bag in Q3 The Lincoln Private Market Index (LPMI) is giving us quite the mixed message this quarter. Up by 2.8%, the index is applauding earnings growth in private companies. Not too shabby, right? Yet, let's not pop the champagne just yet. It's not all sunshine and roses—credit risk clouds are looming large. Steady Performers, but Not...

Lumentum Holders Question Marvell Deal Fairness: Legal Eyes

What's Brewing with Lumentum and Marvell? There's no denying the chatter on Wall Street when there's a potential shake-up, especially with a big merger at stake. We're staring down the barrel of an investigation concerning Lumentum Holdings Inc. (NASDAQ: LITE) and Marvell Technology, Inc.'s deal. The M&A Class Action Firm, helmed by Juan Monteverde, is the name leading...

Fluence Energy Faces Legal Trouble: A Closer Look

Fluence Energy's Legal Tangle: What It Means for Investors You ever get that gut punch feeling when a company you’re watching stumbles? Well, Fluence Energy, Inc. (NASDAQ: FLNC) seems to have handed that to its shareholders lately. There's a class action lawsuit out there that’s got investors not only scratching their heads but also reaching for their phones. The...

EXPO 2027 Belgrade: Serbia's Tourism Game-Changer?

An Unexpected Stage: Belgrade's Big Show Well, who's betting on Belgrade making waves in the global travel scene? EXPO 2027 is shaping up to do just that, and it’s taking the scenic route. Serbia, a country not always on the grand tourist itineraries, could finally hog the spotlight come 2027. Under the banner of 'Play for Humanity: Sport and Music for All,' they're...